Pharmabiz52m
EMA recommends approval of Bluevac-3 and Syvazul BTV 3 vaccines to protect sheep against bluetongue disease
EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 to protect sheep against bluetongue disease. Bluevac-3 is also approved for use in cattle. The disease is caused by the ...
Pharmabiz1h
TN IPA and IDMA to hold an international symposium on ‘Dissolution and Drug Development’ at MMC Chennai on January 23
TN IPA and IDMA to hold an international symposium on ‘Dissolution and Drug Development’ at MMC Chennai on January 23: Our Bureau, Chennai Monday, January 20, 2025, 12:15 Hrs ...
Pharmabiz2h
Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4
Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4: Guangzhou, China Monday, January 20, 2025, 11:00 Hrs [IST] ...
Pharmabiz4h
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...
Pharmabiz4d
Takeda’s flagship GICC to create 750 jobs, foster technological innovation with emphasis on plasma-based therapy
Takeda, a global leader in biopharmaceutical innovation, has inaugurated its flagship Global Innovation Capability Centre (ICC). The Takeda India ICC is a part of Takeda’s Data, Digital & Technology ...
Pharmabiz4d
Chugai Pharma to transfer future marketing of anti-cancer agent, Tarceva tablets 25, 100 & 150 in Japan to Cheplapharm
Chugai Pharmaceutical Co., Ltd. and Cheplapharm K.K. announced that Chugai will transfer the business in Japan concerning the anti-cancer agent Tarceva tablets 25, 100, and 150 to Cheplapharm. Chugai ...
Pharmabiz5h
Indian medical devices & diagnostic sector expects several key measures in Budget 2025 to reduce import dependence
Nandita Vijayasimha, Bengaluru Monday, January 20, 2025, 08:00 Hrs [IST] ...
Pharmabiz4d
NIH-funded study finds cases of ME/CFS increase following SARS-CoV-2
New findings from the National Institutes of Health’s (NIH) Researching Covid to Enhance Recovery (RECOVER) Initiative suggest that infection with SARS-CoV-2, the virus that causes Covid-19, may be ...
Pharmabiz4d
Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, announces that the Scottish Medicines Consortium (SMC) has published recommendations that Agamree (vamorolone) is accepted for use ...
Pharmabiz5d
THE JAN VISHWAS ACT
The Indian Parliament had passed the Jan Vishwas (Amendment of Provisions) Bill, 2023 to remove stringent punishments such as imprisonment from some of the provisions of the Drugs and Cosmetics Act, ...
Pharmabiz4d
REGENXBIO & Nippon Shinyaku enter exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases
REGENXBIO Inc., a leading clinical-stage biotechnology company, and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced a strategic partnership for the development and commercialization of RGX-121 ...
Pharmabiz7d
KPRDO asks FDA to take action against Swiggy & PharmEasy for drug delivery in 10 minutes
The Karnataka Pharma Retailers and Distributors Organization (KPRDO) has now asked the newly formed Karnataka Food and Drug Administration (FDA) to immediately look into the issue of dangerous drug ...